Shanghai, China, Dec 18, 2022 — Aton Biotech, a fast-growing CDMO company which is committed to enabling new biological drugs for clients with an integrated bio-pharmaceutical platform, and Kangabio announced a strategic collaboration. Both parties expressed their aspiration for a long-term, comprehensive and strategic partnership to share resources and achieve joint development on the principle of equality and mutual benefits. During the cooperation, Aton Biotech will provide CDMO services for the innovative drugs of KangaBio, which includes cell line development, cell bank construction and verification, process development and optimization, analytical method development, process transfer and confirmation, clinical manufacturing, commercial scale manufacturing, stability study and IND & NDA filing support, etc.

“KangaBio is a biotech company focused on providing innovative medicine to address unmet medical needs. We are working on developing prodrugs of immune-stimulating agents and other multi-specific biologics to avoid toxicities for previously validated targets and to increase drug efficacy.” said Dr. Weidong Jiang, founder and CEO of Kangabio. “It is a great pleasure to reach this strategic cooperation with Aton Biotech. Aton Biotech has industry-leading antibody drug development, clinical production and commercial production experience and platform advantages, and has established a quality system that meets international GMP requirements. It is hoped that based on the existing projects, the cooperation between the two parties will continue to deepen, so as to benefit patients as soon as possible with better innovative drugs.”

“Aton Biotech is very pleased to provide CDMO services for KangaBio, and we are very grateful for the trust from KangaBio.” said Ms. Wei Huang, COO and SVP of Henlius and Chairman of Aton Biotech. “Aton Biotech is committed to enabling new biological drugs for clients with an integrated bio-pharmaceutical platform and has accumulated rich experience in many areas such as process development, manufacturing and regulatory. Aton Biotech will continue to uphold the concept of ‘quality, integrity, efficient, excellence’, and look forward to more in-depth cooperation between the two parties in the future to accelerate KangaBio’s molecule to market and benefit more patients.”

About Kangabio

KangaBio is a biotech company focused on providing innovative medicine to address unmet medical needs. We are working on developing prodrugs of immune-stimulating agents and other multi-specific biologics to avoid toxicities for previously validated targets and to increase drug efficacy.

Dr. Jiang previously co-founded Shanghai Henlius Biotech in 2010, a public company listed on Hong Kong stock exchange with five successfully launched biologics in the Chinese market as well as one in the European market. KangaBio is growing rapidly and recruiting global talent, centering core values on efficiency, innovation, competition & collaboration, and win-win.